A recent study found that antiretroviral therapy adherence below 90% was associated with significantly lower odds of viral suppression among women living with HIV. Researchers analyzed data from ...

Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

In the early 1980s, as a physician at the University of California Medical Center, researching and treating sexually transmitted viral diseases, I found myself at the epicenter of an emerging crisis ...

High stigma levels correlate with lower ART adherence and viral suppression in women with HIV, especially those who inject drugs. The study used data from the WIHS, focusing on stigma's impact on HIV ...

This study assessed longitudinal relationships between patient healthcare empowerment, engagement in care, and viral control in the Women's Interagency HIV Study, a prospective cohort study of U.S.

HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but ...

GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control. Now, the injection has beaten daily drugs in individuals ...

Self-reported measures of antiretroviral adherence vary greatly in recall time periods and response tasks. To determine which time frame is most accurate, we compared 3-, 7-day, and 1-month ...

New guidelines update ART choices, endorse long-acting injectables, refine infant feeding advice, and prioritise shorter TB ...

Forty years ago, the U.S. Centers for Disease Control and Prevention (CDC) first sounded the alarm that Black and Latino communities were disproportionately ...

Thousands in Florida who rely on the AIDS Drug Assistance Program will see their coverage cut or their medication changed, ...